{"entity":{"id":"briacell","kind":"company","name":"BriaCell Therapeutics","aka":["BriaCell Therapeutics Corp","BriaCell Therapeutics Corporation","BriaCell"],"tldr":"BriaCell Therapeutics is a listed company developing off-the-shelf immunotherapies made from cancer cells grown in the laboratory. Its lead treatment, Bria-IMT, is in a phase 3 trial in metastatic breast cancer, and a related platform, Bria-OTS, is in an earlier trial.","summary":"BriaCell Therapeutics Corp. describes itself as a clinical-stage immuno-oncology company, with a corporate office in West Vancouver, British Columbia, and a United States office in Philadelphia; it is listed on Nasdaq (BCTX) and the Toronto Stock Exchange (BCT). Its lead candidate Bria-IMT is described by the company as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor in a pivotal phase 3 study in metastatic breast cancer; the company states that the FDA granted it Fast Track status. That study, NCT06072612 (BRIA-ABC), compares the Bria-IMT regimen with a checkpoint inhibitor against treatment of the physician's choice. Bria-OTS is a platform of personalised off-the-shelf cell-based immunotherapies in a phase 1/2 study, initially in breast cancer, with prostate cancer named as the next indication. In fiscal year 2026 NCI awarded the company USD 947,870 under SBIR Phase II grant 5R44CA281555-03 for an off-the-shelf tumour cell vaccine with HLA-matching alleles for advanced metastatic prostate cancer.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://briacell.com/"},{"label":"NIH RePORTER: award 5R44CA281555-03","url":"https://reporter.nih.gov/project-details/11398997"},{"label":"ClinicalTrials.gov: BRIA-ABC phase 3 trial (NCT06072612)","url":"https://clinicaltrials.gov/study/NCT06072612"}],"tags":[],"related":[],"cancers":["breast-cancer","prostate"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":["bria-imt","bria-ots"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06072612"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Offices, listings, pipeline and the Fast Track statement read on briacell.com, and the award on NIH RePORTER, on 4 November 2026. The Fast Track statement is the company's; the FDA does not publish Fast Track grants."],"hq":"West Vancouver, BC","country":"CA","companyType":"biotech","website":"https://briacell.com/","ticker":"BCTX","stage":"public","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":947870,"source":"https://reporter.nih.gov/project-details/11398997","note":"NCI SBIR Phase II (R44) award 5R44CA281555-03: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer"}]},"route":"/companies/briacell/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"drug":[{"id":"bria-imt","kind":"drug","name":"Bria-IMT","route":"/drugs/bria-imt/"},{"id":"bria-ots","kind":"drug","name":"Bria-OTS","route":"/drugs/bria-ots/"}],"trial":[{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/"}]}}